About this trial
This is a Phase 1-2, multicenter, international, single-arm, open-label study designed to identify a recommended dose of bosutinib administered orally once daily in pediatric patients with CML who have received at least one prior TKI therapy, and to preliminary estimate the efficacy, safety, and tolerability of the selected bosutinib dose and evaluate the PK in this patient population.
Patient Profile
CML resistant/intolerant to at least one prior Tyrosine Kinase Inhibitor treatment.
Where’s this trial being run?
Crumlin Children’s Hospital
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | ITCC 054 |
|---|---|
| Number: | 18-24 |
| Full Title: | A phase I/II study of Bosutinib in pediatric patients with Chronic Myeloid Leukemia who are resistant or intolerant to at least one prior Tyrosine Kinase Inhibitor therapy, ITCC-054. |
| Principal Investigator: | Dr Owen Smith |
|---|---|
| Type: | Collaborative |
| Sponsor: | Erasmus Medical Centre |
| Recruitment Started: |
Global: Not Available Ireland: Not Available |
| Global Recruitment Target: | Not Available |
|---|---|
| Ireland Recruitment Target: | Not Available |